Have a feature idea you'd love to see implemented?
Let us know!
SMMT Summit Therapeutics Inc
Price (delayed)
$16.65
Market cap
$12.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$12.22B
Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader
Highlights
SMMT's equity has surged by 124% since the previous quarter
The EPS has soared by 100% YoY
The net income has soared by 67% YoY but it has contracted by 22% from the previous quarter
Key stats
What are the main financial stats of SMMT
Market
Valuations
Earnings
Shares outstanding
737.45M
Market cap
$12.28B
Enterprise value
$12.22B
Price to earnings (P/E)
N/A
Price to book (P/B)
27.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$196.68M
EBIT
-$196.68M
EBITDA
-$196.01M
Free cash flow
-$113.02M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$0.16
Book value per share
$0.6
Revenue per share
$0
TBVPS
$0.69
Total assets
$502.85M
Total liabilities
$64.93M
Debt
$32.5M
Equity
$437.92M
Working capital
$431.28M
Debt to equity
0.07
Current ratio
8.31
Quick ratio
8.26
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-64.3%
Return on equity
-104.2%
Return on invested capital
-73.2%
Return on capital employed
-44.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SMMT stock price
How has the Summit Therapeutics stock price performed over time
Intraday
-8.39%
1 week
-8.31%
1 month
-6.62%
1 year
437.1%
YTD
-6.7%
QTD
-6.7%
Financial performance
How have Summit Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$196.59M
Net income
-$196.68M
Gross margin
N/A
Net margin
N/A
The operating income has soared by 67% YoY but it has contracted by 24% from the previous quarter
The net income has soared by 67% YoY but it has contracted by 22% from the previous quarter
Growth
What is Summit Therapeutics's growth rate over time
Valuation
What is Summit Therapeutics stock price valuation
P/E
N/A
P/B
27.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 100% YoY
SMMT's equity has surged by 124% since the previous quarter
The P/B is 109% above the 5-year quarterly average of 13.2 but 28% below the last 4 quarters average of 38.4
Efficiency
How efficient is Summit Therapeutics business performance
The company's return on equity has surged by 79% YoY and by 33% QoQ
The ROA has soared by 63% YoY and by 7% from the previous quarter
SMMT's return on invested capital has surged by 62% year-on-year
Dividends
What is SMMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SMMT.
Financial health
How did Summit Therapeutics financials performed over time
SMMT's total assets has soared by 130% YoY and by 47% from the previous quarter
The total liabilities has dropped by 56% since the previous quarter and by 45% year-on-year
The debt is 93% smaller than the equity
SMMT's equity has surged by 124% since the previous quarter
Summit Therapeutics's debt to equity has plunged by 93% YoY and by 88% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.